Palisade Bio Inc PALI shares are trading lower by 31.82% to $2.40 after the company announced a $6 million registered direct offering and concurrent private placement priced above the market under Nasdaq rules.
Palisade Bio says certain investors will receive a portion of their investment in unregistered shares or unregistered pre-funded warrants in the private placement in lieu of registered common stock.
See Also: Warren Buffett-Backed BYD Posts 91% Jump in March EV Deliveries
Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes.
According to data from Benzinga Pro, Palisade Bio has a 52-week high of $53.45 and a 52-week low of $1.55.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
